Protease-activated drug development

Theranostics

Volumn 2, Issue 2, 2012, Pages 156-179

  Choi, Ki Young ^a   Swierczewska, Magdalena ^a,b   Lee, Seulki ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b St Francis Hospital The Heart Center   (United States)

Author keywords

Activatable probe; Alzheimer's disease; Aspartyl protease; Cancer; Caspase; Cathepsin; Kallikrein; MMP; Protease; PSA; Serine protease

Indexed keywords

BIOLOGICAL MARKER; BRENTUXIMAB VEDOTIN; C 1853; CASPASE; CATHEPSIN B; CATHEPSIN D; CATHEPSIN E; CATHEPSIN K; CATHEPSIN L; COLLAGENASE 3; COPOLYMER; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; FCE 28068; FCE 28069; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; KALLIKREIN; L 377202; MONOCLONAL ANTIBODY; NEUTROPHIL COLLAGENASE; PACLITAXEL POLIGLUMEX; PLASMIN; POLYPEPTIDE; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEASE ACTIVATED PRODRUG; PROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR;

AMINO ACID SEQUENCE; BREAST CARCINOMA; CARCINOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONJUGATE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONJUGATION; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME LOCALIZATION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LETHAL DOSE; LEUKEMIA L 1210; LIVER CANCER; LUNG CARCINOMA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MACROMOLECULE; NONHUMAN; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT INDICATION;

EID: 84864572139     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4068     Document Type: Review

References (261)

1. Lopez-Otin C and Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer. 2010; 10: 278-92.
2. Lopez-Otin C and Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007; 7: 800-8.
3. Turk B. Targeting proteases: Successes, failures and future prospects. Nat Rev Drug Discov. 2006; 5: 785-99.
4. Lopez-Otin C and Bond JS. Proteases: Multifunctional enzymes in life and disease. J Biol Chem. 2008; 283: 30433-7.
5. Orlowski RZ and Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res. 2008; 14: 1649-57.
6. Horiguchi A, Zheng R, Goodman OB, Jr., et al. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Ther. 2007; 14: 583-9.
7. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the x-linked inhibitor of apoptosis protein. Mol Cancer Ther. 2007; 6: 957-66.
8. Jang B and Choi Y. Photosensitizer-conjugated gold nanorods for enzyme-activatable fluorescence imaging and photodynamic therapy. Theranostics. 2012; 2: e0005.
9. Kim GB and Kim Y-P. Analysis of protease activity using quantum dots. Theranostics. 2012; 2: e0004.
10. Yhee JY, Kinm SA, Koo HB, et al. Optical imaging of cancer-related proteases using near-infrared fluorescence matrix metalloproteinase-sensitive and cathepsin b-sensitive probes. Theranostics. 2012; 2: e0017.
11. Zhu L, Xie J, Swierczewska M, et al. Real-time video imaging of protease expression in vivo. Theranostics. 2011; 1: 18-27.
12. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nat Rev Drug Discov. 2008; 7: 255-70.
13. Mahato R, Tai W, and Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011; 63: 659-70.
14. Stella VJ. Prodrugs as therapeutics. Expert Opin Ther Pat. 2004; 14: 277-80.
15. Borgono CA and Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004; 4: 876-90.
16. Gabriel D, Zuluaga MF, Van Den Bergh H, et al. It is all about proteases: From drug delivery to in vivo imaging and photomedicine. Curr Med Chem. 2011; 18: 1785-805.
17. Coussens LM and Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-7.
18. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4: 71-8.
19. Mohamed MM and Sloane BF. Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer. 2006; 6: 764-75.
20. Flannery T, Gibson D, Mirakhur M, et al. The clinical significance of cathepsin s expression in human astrocytomas. Am J Pathol. 2003; 163: 175-82.
21. Mikkelsen T, Yan PS, Ho KL, et al. Immunolocalization of cathepsin b in human glioma: Implications for tumor invasion and angiogenesis. J Neurosurg. 1995; 83: 285-90.
22. Sloane BF, Honn KV, Sadler JG, et al. Cathepsin-b activity in b-16 melanoma-cells - a possible marker for metastatic potential. Cancer Res. 1982; 42: 980-6.
23. Hughes SJ, Glover TW, Zhu X-X, et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin b in esophageal adenocarcinoma. Proc Natl Acad Sci U S A. 1998; 95: 12410-5.
24. Krueger S, Kalinski T, Hundertmark T, et al. Up-regulation of cathepsin x in helicobacter pylori gastritis and gastric cancer. J Pathol. 2005; 207: 32-42.
25. Campo E, Munoz J, Miquel R, et al. Cathepsin b expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 1994; 145: 301-9.
26. Fernández PL, Farré X, Nadal A, et al. Expression of cathepsins b and s in the progression of prostate carcinoma. Int J Cancer. 2001; 95: 51-5.
27. Nägler DK, Krüger S, Kellner A, et al. Up-regulation of cathepsin x in prostate cancer and prostatic intraepithelial neoplasia. Prostate. 2004; 60: 109-19.
28. Santamaría I, Velasco G, Cazorla M, et al. Cathepsin l2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 1998; 58: 1624-30.
29. Linnerth NM, Sirbovan K, and Moorehead RA. Use of a transgenic mouse model to identify markers of human lung tumors. Int J Cancer. 2005; 114: 977-82.
30. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-26.
31. Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin k. J Biol Chem. 1996; 271: 12517-24.
32. Xia L, Kilb J, Wex H, et al. Localization of rat cathepsin k in osteoclasts and resorption pits: Inhibition of bone resorption and cathepsin k-activity by peptidyl vinyl sulfones. Biol Chem. 1999; 380: 679-87.
33. Gocheva V and Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007; 6: 60-4.
34. Palermo C and Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2008; 29: 22-8.
35. Buck MR, Karustis DG, Day NA, et al. Degradation of extracellular-matrix proteins by human cathepsin b from normal and tumour tissues. Biochem J. 1992; 282 (Pt 1): 273-8.
36. Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006; 20: 543-56.
37. Yan S and Sloane BF. Molecular regulation of human cathepsin b: Implication in pathologies. Biol Chem. 2003; 384: 845-54.
38. Cavallo-Medved D, Mai J, Dosescu J, et al. Caveolin-1 mediates the expression and localization of cathepsin b, prourokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci. 2005; 118: 1493-503.
39. Boya P and Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008; 27: 6434-51.
40. + exchanger in metastasis. Nat Rev Cancer. 2005; 5: 786-95.
41. Reddy VY, Zhang QY, and Weiss SJ. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins b, l, and s, by human monocyte-derived macrophages. Proc Natl Acad Sci U S A. 1995; 92: 3849-53.
42. Cirman T, Orešić K, Mazovec GD, et al. Selective disruption of lysosomes in hela cells triggers apoptosis mediated by cleavage of bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004; 279: 3578-87.
43. Stoka V, Turk B, Schendel SL, et al. Lysosomal protease pathways to apoptosis - cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem. 2001; 276: 3149-57.
44. Vasiljeva O and Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: Apoptosis versus tumour invasion. Biochimie. 2008; 90: 380-6.
45. Reinheckel T, Hagemann S, Dollwet-Mack S, et al. The lysosomal cysteine protease cathepsin l regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci. 2005; 118: 3387-95.
46. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; 5: 443-53.
47. Conover CA, Perry JE, and Tindall DJ. Endogenous cathepsin d-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic-carcinoma cells. J Clin Endocrinol Metab. 1995; 80: 987-93.
48. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin-d and prognosis in breast-cancer. N Engl J Med. 1990; 322: 297-302.
49. Ma YM, Zhao M, Zhong JL, et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem. 2010; 110: 1512-9.
50. Zaidi N, Hermann C, Herrmann T, et al. Emerging functional roles of cathepsin e. Biochem Biophys Res Commun. 2008; 377: 327-30.
51. Matsuo K, Kobayashi I, Tsukuba T, et al. Immunohistochemical localization of cathepsins d and e in human gastric cancer: A possible correlation with local invasive and metastatic activities of carcinoma cells. Hum Pathol. 1996; 27: 184-90.
52. Tenti P, Romagnoli S, Silini E, et al. Cervical adenocarcinomas express markers common to gastric, intestinal, and pancreatobiliary epithelial cells. Pathol Res Pract. 1994; 190: 342-9.
53. Uno K, Azuma T, Nakajima M, et al. Clinical significance of cathepsin e in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2000; 15: 1333-8.
54. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002; 160: 1745-54.
55. Ullmann R, Morbini P, Halbwedl I, et al. Protein expression profiles in adenocarcinomas and squamous cell carcinomas of the lung generated using tissue microarrays. J Pathol. 2004; 203: 798-807.
56. Cleutjens KBJM, Van Eekelen CCEM, Van Der Korput HaGM, et al. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem. 1996; 271: 6379-88.
57. Malm J, Hellman J, Hogg P, et al. Enzymatic action of prostate-specific antigen (psa or hk3): Substrate specificity and regulation by zn2+, a tight-binding inhibitor. Prostate. 2000; 45: 132-9.
58. Yousef GM and Diamandis EP. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev. 2001; 22: 184-204.
59. Réhault S, Monget P, Mazerbourg S, et al. Insulin-like growth factor binding proteins (igfbps) as potential physiological substrates for human kallikreins hk2 and hk3. Eur J Biochem. 2001; 268: 2960-8.
60. Mikolajczyk SD, Millar LS, Kumar A, et al. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer. 1999; 81: 438-42.
61. Takayama TK, Mcmullen BA, Nelson PS, et al. Characterization of hk4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-psa) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry. 2001; 40: 15341-8.
62. Yoshida E, Ohmura S, Sugiki M, et al. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer. 1995; 63: 863-5.
63. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001; 21: 1104-17.
64. Killian CS, Corral DA, Kawinski E, et al. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent tgf-β and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun. 1993; 192: 940-7.
65. Fortier AH, Nelson BJ, Grella DK, et al. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 1999; 91: 1635-40.
66. Desriviéres S, Lu H, Peyri N, et al. Activation of the 92 kda type iv collagenase by tissue kallikrein. J Cell Physiol. 1993; 157: 587-93.
67. Andreasen PA, Egelund R, and Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000; 57: 25-40.
68. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000; 60: 636-43.
69. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen-activator is expressed in stromal cells and its receptor in cancer-cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991; 138: 1059-67.
70. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst. 1999; 91: 869-74.
71. Duffy MJ, Maguire TM, Mcdermott EW, et al. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer. J Surg Oncol. 1999; 71: 130-5.
72. Miyake H, Hara I, Yamanaka K, et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 1999; 39: 123-9.
73. Dass K, Ahmad A, Azmi AS, et al. Evolving role of upa/upar system in human cancers. Cancer Treat Rev. 2008; 34: 122-36.
74. Jin E, Fujiwara M, Pan X, et al. Protease-activated receptor (par)-1 and par-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer. 2003; 97: 703-13.
75. Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 2000; 275: 26333-42.
76. Darmoul D, Gratio V, Devaud H, et al. Protease-activated receptor 2 in colon cancer. J Biol Chem. 2004; 279: 20927-34.
77. Morris DR, Ding Y, Ricks TK, et al. Protease-activated receptor-2 is essential for factor viia and xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006; 66: 307-14.
78. Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (par1 and par2) contribute to tumor cell motility and metastasis. Mol Cancer Res. 2004; 2: 395-402.
79. Hengartner MO. The biochemistry of apoptosis. Nature. 2000; 407: 770-6.
80. Thornberry NA and Lazebnik Y. Caspases: Enemies within. Science. 1998; 281: 1312-6.
81. Leist M and Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001; 2: 589-98.
82. Hunter AM, Lacasse EC, and Korneluk RG. The inhibitors of apoptosis (iaps) as cancer targets. Apoptosis. 2007; 12: 1543-68.
83. Klein T and Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011; 41: 271-90.
84. Ra H-J and Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007; 26: 587-96.
85. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997; 378: 151-60.
86. Page-Mccaw A, Ewald AJ, and Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007; 8: 221-33.
87. Chakrabarti S and Patel KD. Matrix metalloproteinase-2 (mmp-2) and mmp-9 in pulmonary pathology. Exp Lung Res. 2005; 31: 599-621.
88. Nguyen M, Arkell J, and Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001; 33: 960-70.
89. Bergers G, Brekken R, Mcmahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2: 737-44.
90. Van Den Steen PE, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase b or matrix metalloproteinase-9 (mmp-9). Crit Rev Biochem Mol Biol. 2002; 37: 375-536.
91. Somiari SB, Somiari RI, Heckman CM, et al. Circulating mmp2 and mmp9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006; 119: 1403-11.
92. Turpeenniemi-Hujanen T. Gelatinases (mmp-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005; 87: 287-97.
93. Ranuncolo SM, Armanasco E, Cresta C, et al. Plasma mmp-9 (92 kda-mmp) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer. 2003; 106: 745-51.
94. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (mmp)-2, mmp-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001; 7: 2396-404.
95. Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses. Int J Cancer. 1997; 72: 556-64.
96. Zucker S and Vacirca J. Role of matrix metalloproteinases (mmps) in colorectal cancer. Cancer Metastasis Rev. 2004; 23: 101-17.
97. Forsyth PA, Wong H, Laing TD, et al. Gelatinase-a (mmp-2), gelatinase-b (mmp-9) and membrane type matrix metalloproteinase-1 (mt1-mmp) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999; 79: 1828-35.
98. Yong VW, Power C, Forsyth P, et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001; 2: 502-11.
99. Ii M, Yamamoto H, Adachi Y, et al. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med. 2006; 231: 20-7.
100. Wang F, Reierstad S, and Fishman DA. Matrilysin over-expression in mcf-7 cells enhances cellular invasiveness and progelatinase activation. Cancer Lett. 2006; 236: 292-301.
101. Coussens LM, Fingleton B, and Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 2002; 295: 2387-92.
102. Nagase H, Visse R, and Murphy G. Structure and function of matrix metalloproteinases and timps. Cardiovasc Res. 2006; 69: 562-73.
103. Nagase H and Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999; 274: 21491-4.
104. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol. 2000; 18: 1135.
105. Mattson MP. Pathways towards and away from alzheimer's disease. Nature. 2004; 430: 631-9.
106. Selkoe DJ and Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol and Toxicol. 2003; 43: 545-84.
107. Lichtenthaler SF, Haass C, and Steiner H. Regulated intramembrane proteolysis - lessons from amyloid precursor protein processing. J Neurochem. 2011; 117: 779-96.
108. Janus C, Pearson J, Mclaurin J, et al. A [beta] peptide immunization reduces behavioural impairment and plaques in a model of alzheimer's disease. Nature. 2000; 408: 979-82.
109. Nicoll JaR, Wilkinson D, Holmes C, et al. Neuropathology of human alzheimer disease after immunization with amyloid-[beta] peptide: A case report. Nat Med. 2003; 9: 448-52.
110. Diamandis EP, Yousef GM, Petraki C, et al. Human kallikrein 6 as a biomarker of alzheimer's disease. Clin Biochem. 2000; 33: 663-7.
111. Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in alzheimer disease. Nat Rev Neurol. 2010; 6: 131-44.
112. Edwards DR, Handsley MM, and Pennington CJ. The adam metalloproteinases. Mol Asp Med. 2008; 29: 258-89.
113. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107: 598-603.
114. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats - inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998; 29: 1020-30.
115. Zhang KY, Mcquibban GA, Silva C, et al. Hiv-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci. 2003; 6: 1064-71.
116. Lee CG, Homer R, Zhou Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001; 194: 809-21.
117. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev. 2007; 87: 1285-342.
118. Zaman MA, Oparil S, and Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002; 1: 621-36.
119. Jessup M and Brozena S. Heart failure. N Engl J Med. 2003; 348: 2007-18.
120. Holland OB, Chud JM, and Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest. 1980; 65: 347-56.
121. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta. 2004; 342: 41-69.
122. Albert A. Chemical aspects of selective toxicity. Nature. 1958; 182: 421-2.
123. Law B and Tung CH. Proteolysis: A biological process adapted in drug delivery, therapy, and imaging. Bioconjug Chem. 2009; 20: 1683-95.
124. Baurain R, Masquelier M, Deprez-De Campeneere D, et al. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on l1210 leukemic cells in vitro and in vivo. J Med Chem. 1980; 23: 1171-4.
125. Boven E, Hendriks HR, Erkelens CA, et al. The anti-tumour effects of the prodrugs n-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br J Cancer. 1992; 66: 1044-7.
126. Breistol K, Hendriks HR, Berger DP, et al. The antitumour activity of the prodrug n-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. Eur J Cancer. 1998; 34: 1602-6.
127. Breistol K, Hendriks HR, and Fodstad O. Superior therapeutic efficacy of n-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. Eur J Cancer. 1999; 35: 1143-9.
128. De Jong J, Klein I, Bast A, et al. Analysis and pharmacokinetics of n-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing balb/c mice. Cancer Chemother Pharmacol. 1992; 31: 156-60.
129. Deprez-De Campeneere D, Baurain R, and Trouet A. Accumulation and metabolism of new anthracycline derivatives in the heart after iv injection into mice. Cancer Chemother Pharmacol. 1982; 8: 193-7.
130. Zbinden G, Decampeenere D, and Baurain R. Preclinical assessment of the cardiotoxic potential of anthracycline antibiotics: N-l-leucyl-doxorubicin. Arch Toxicol Suppl. 1991; 14: 107-17.
131. Trouet A, Masquelier M, Baurain R, et al. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies. Proc Natl Acad Sci U S A. 1982; 79: 626-9.
132. Matsumura Y and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-92.
133. Maeda H and Matsumura Y. Epr effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev. 2011; 63: 129-30.
134. Duncan R, Coatsworth JK, and Burtles S. Preclinical toxicology of a novel polymeric antitumour agent: Hpma copolymer-doxorubicin (pk1). Hum Exp Toxicol. 1998; 17: 93-104.
135. Loadman PM, Bibby MC, Double JA, et al. Pharmacokinetics of pk1 and doxorubicin in experimental colon tumor models with differing responses to pk1. Clin Cancer Res. 1999; 5: 3682-8.
136. Malugin A, Kopeckova P, and Kopecek J. Liberation of doxorubicin from hpma copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release. 2007; 124: 6-10.
137. Minko T, Kopeckova P, and Kopecek J. Comparison of the anticancer effect of free and hpma copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res. 1999; 16: 986-96.
138. Minko T, Kopeckova P, Pozharov V, et al. Hpma copolymer bound adriamycin overcomes mdr1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release. 1998; 54: 223-33.
139. Seymour LW, Ulbrich K, Strohalm J, et al. The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol. 1990; 39: 1125-31.
140. Yeung TK, Hopewell JW, Simmonds RH, et al. Reduced cardiotoxicity of doxorubicin given in the form of n-(2-hydroxypropyl)methacrylamide conjugates: And experimental study in the rat. Cancer Chemother Pharmacol. 1991; 29: 105-11.
141. Duncan R, Kopeckova P, Strohalm J, et al. Anticancer agents coupled to n-(2-hydroxypropyl)methacrylamide copolymers. Ii. Evaluation of daunomycin conjugates in vivo against l1210 leukaemia. Br J Cancer. 1988; 57: 147-56.
142. Putnam D and Kopecek J. Enantioselective release of 5-fluorouracil from n-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. Bioconjug Chem. 1995; 6: 483-92.
143. Gianasi E, Buckley RG, Latigo J, et al. Hpma copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J Drug Target. 2002; 10: 549-56.
144. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of hpma copolymer and tnp-470. Nat Med. 2004; 10: 255-61.
145. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998; 58: 2404-9.
146. Shaffer SA, Baker-Lee C, Kennedy J, et al. In vitro and in vivo metabolism of paclitaxel poliglumex: Identification of metabolites and active proteases. Cancer Chemother Pharmacol. 2007; 59: 537-48.
147. Denmeade SR, Lou W, Lovgren J, et al. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. 1997; 57: 4924-30.
148. Denmeade SR, Nagy A, Gao J, et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998; 58: 2537-40.
149. Khan SR and Denmeade SR. In vivo activity of a psa-activated doxorubicin prodrug against psa-producing human prostate cancer xenografts. Prostate. 2000; 45: 80-3.
150. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003; 95: 990-1000.
151. Jakobsen CM, Denmeade SR, Isaacs JT, et al. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem. 2001; 44: 4696-703.
152. Mhaka A, Denmeade SR, Yao W, et al. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett. 2002; 12: 2459-61.
153. Defeo-Jones D, Garsky VM, Wong BK, et al. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med. 2000; 6: 1248-52.
154. Chandran SS, Nan A, Rosen DM, et al. A prostate-specific antigen activated n-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther. 2007; 6: 2928-37.
155. Kratz F, Mansour A, Soltau J, et al. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm (Weinheim). 2005; 338: 462-72.
156. Graeser R, Chung DE, Esser N, et al. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (psa) in a psa-positive orthotopic prostate carcinoma model (lncap). Int J Cancer. 2008; 122: 1145-54.
157. Albright CF, Graciani N, Han W, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit ht1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther. 2005; 4: 751-60.
158. Kline T, Torgov MY, Mendelsohn BA, et al. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9. Mol Pharm. 2004; 1: 9-22.
159. Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003; 63: 4062-6.
160. Chau Y, Tan FE, and Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase ii and matrix metalloproteinase ix. Bioconjug Chem. 2004; 15: 931-41.
161. Chau Y, Dang NM, Tan FE, et al. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. J Pharm Sci. 2006; 95: 542-51.
162. Alley SC, Okeley NM, and Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol. 2010; 14: 529-37.
163. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009; 13: 235-44.
164. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 21: 778-84.
165. [Internet] FDA. Fda approves adcetris to treat two types of lympoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268781.htm.
166. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of pk1 [n-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer research campaign phase I/II committee. Clin Cancer Res. 1999; 5: 83-94.
167. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20: 1668-76.
168. Duncan R. Development of hpma copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009; 61: 1131-48.
169. Greco F and Vicent MJ. Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009; 61: 1203-13.
170. Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (pk1, fce28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009; 34: 1629-36.
171. Duncan R and Vicent MJ. Do hpma copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev. 2010; 62: 272-82.
172. De Groot FM, Broxterman HJ, Adams HP, et al. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol Cancer Ther. 2002; 1: 901-11.
173. Yoneda Y, Steiniger SC, Capkova K, et al. A cell-penetrating peptidic grp78 ligand for tumor cell-specific prodrug therapy. Bioorg Med Chem Lett. 2008; 18: 1632-6.
174. Kawakami S, Munakata C, Fumoto S, et al. Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J Pharm Sci. 2001; 90: 105-13.
175. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-cd30-auristatin conjugates. J Biol Chem. 2006; 281: 10540-7.
176. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006; 66: 4426-33.
177. Brigger I, Dubernet C, and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54: 631-51.
178. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin k is expressed in human breast carcinoma. Cancer Res. 1997; 57: 5386-90.
179. Liu JA, Sukhova GK, Sun JS, et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 1359-66.
180. Sukhova GK, Shi GP, Simon DI, et al. Expression of the elastolytic cathepsins s and k in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998; 102: 576-83.
181. Bromme D and Lecaille F. Cathepsin k inhibitors for osteoporosis and potential off-target effects. Expert Opin Invest Drugs. 2009; 18: 585-600.
182. Costa AG, Cusano NE, Silva BC, et al. Cathepsin k: Its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011; 7: 447-56.
183. Sinha AA, Wilson MJ, Gleason DF, et al. Immunohistochemical localization of cathepsin-b in neoplastic human prostate. Prostate. 1995; 26: 171-8.
184. Bongers V, Konings CH, Grijpma AM, et al. Serum proteinase activities in head and neck squamous cell carcinoma patients. Anticancer Res. 1995; 15: 2763-6.
185. Lopez Couto E, Tersariol ILS, Pinhal MaS, et al. Cathepsin b and heparanase activity and expression in head and neck squamous cell carcinoma. Oral Oncol. 2007;: 96.
186. Roshy S, Sloane BF, and Moin K. Pericellular cathepsin b and malignant progression. Cancer Metastasis Rev. 2003; 22: 271-86.
187. Zhang H, Fu T, Mcgettigan S, et al. Il8 and cathepsin b as melanoma serum biomarkers. Int J Mol Sci. 2011; 12: 1505-18.
188. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1 beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A. 1997; 94: 2007-12.
189. Schellmann N, Deckert PM, Bachran D, et al. Targeted enzyme prodrug therapies. Mini Rev Med Chem. 2010; 10: 887-904.
190. Martinon F and Tschopp J. Inflammatory caspases: Linking an intracellular innate immune system to autoinflammatory diseases. Cell. 2004; 117: 561-74.
191. Huttunen KM and Rautio J. Prodrugs - an efficient way to breach delivery and targeting barriers. Curr Top Med Chem. 2011; 11: 2265-87.
192. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in parkinson's disease. Proc Natl Acad Sci U S A. 2000; 97: 2875-80.
193. Li MW, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an als transgenic mouse model. Science. 2000; 288: 335-9.
194. Huttunen KM, Raunio H, and Rautio J. Prodrugs-from serendipity to rational design. Pharmacol Rev. 2011; 63: 750-71.
195. Ona VO, Li MW, Vonsattel JPG, et al. Inhibition of caspase-1 slows disease progression in a mouse model of huntington's disease. Nature. 1999; 399: 263-7.
196. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999; 79: 1431-568.
197. Yoshiyama Y, Arai K, Oki T, et al. Expression of invariant chain and procathepsin l in alzheimer's brain. Neurosci Lett. 2000; 290: 125-8.
198. Johnson MD, Torri JA, Lippman ME, et al. The role of cathepsin-d in the invasiveness of human breast-cancer cells. Cancer Res. 1993; 53: 873-7.
199. Losch A, Schindl M, Kohlberger P, et al. Cathepsin d in ovarian cancer: Prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol. 2004; 92: 545-52.
200. Tedone T, Correale M, Barbarossa G, et al. Release of the aspartyl protease cathepsin d is associated with and facilitates human breast cancer cell invasion. FASEB J. 1997; 11: 785-92.
201. Reynolds MA, Kastury K, Groskopf J, et al. Molecular markers for prostate cancer. Cancer Lett. 2007; 249: 5-13.
202. Adib TR, Henderson S, Perrett C, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer. 2004; 90: 686-92.
203. Yousef GM, Borgono CA, Popalis C, et al. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res. 2004; 24: 43-52.
204. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004; 10: 3291-300.
205. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas. Cancer Res. 2003; 63: 8614-22.
206. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004; 5: 489-500.
207. Yousef GM, Scorilas A, Katsaros D, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol. 2003; 21: 3119-26.
208. Yousef GM, Scorilas A, Jung K, et al. Molecular cloning of the human kallikrein 15 gene (klk15). J Biol Chem. 2001; 276: 53-61.
209. Trengove NJ, Stacey MC, Macauley S, et al. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Repair Regen. 1999; 7: 442-52.
210. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002; 39: 279-91.
211. Egeblad M and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-74.
212. Heppner KJ, Matrisian LM, Jensen RA, et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996; 149: 273-82.
213. Peake NJ, Khawaja K, Myers A, et al. Levels of matrix metalloproteinase (mmp)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: Relationship to inflammatory activity, mmp-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology. 2005; 44: 1383-9.
214. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation. 2004; 110: 337-43.
215. Chen J, Stefflova K, Niedre MJ, et al. Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc. 2004; 126: 11450-1.
216. Stefflova K, Chen J, Marotta D, et al. Photodynamic therapy agent with a built-in apoptosis sensor for evaluating its own therapeutic outcome in situ. J Med Chem. 2006; 49: 3850-6.
217. Carter PJ and Gazzard L. Caspase activated prodrugs therapy. Wip organization. 2001.
218. Kuefner U, Lohrmann U, Montejano YD, et al. Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides. Biochemistry. 1989; 28: 2288-97.
219. Lo PC, Chen J, Stefflova K, et al. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J Med Chem. 2009; 52: 358-68.
220. Janssen S, Jakobsen CM, Rosen DM, et al. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Mol Cancer Ther. 2004; 3: 1439-50.
221. Janssen S, Rosen DM, Ricklis RM, et al. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hk2)-activated thapsigargin prodrug. Prostate. 2006; 66: 358-68.
222. Chen J, Liu TW, Lo PC, et al. "Zipper" molecular beacons: A generalized strategy to optimize the performance of activatable protease probes. Bioconjug Chem. 2009; 20: 1836-42.
223. Zheng G, Chen J, Stefflova K, et al. Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci U S A. 2007; 104: 8989-94.
224. De Groot FM, De Bart AC, Verheijen JH, et al. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin. J Med Chem. 1999; 42: 5277-83.
225. Carl PL, Chakravarty PK, and Katzenellenbogen JA. A novel connector linkage applicable in prodrug design. J Med Chem. 1981; 24: 479-80.
226. Chakravarty PK, Carl PL, Weber MJ, et al. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. J Med Chem. 1983; 26: 633-8.
227. Carl PL, Chakravarty PK, Katzenellenbogen JA, et al. Protease-activated "prodrugs" for cancer chemotherapy. Proc Natl Acad Sci U S A. 1980; 77: 2224-8.
228. Balajthy Z, Aradi J, Kiss IT, et al. Synthesis and functional evaluation of a peptide derivative of 1-beta-d-arabinofuranosylcytosine. J Med Chem. 1992; 35: 3344-9.
229. Devy L, De Groot FM, Blacher S, et al. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. FASEB J. 2004; 18: 565-7.
230. De Groot FM, Loos WJ, Koekkoek R, et al. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J Org Chem. 2001; 66: 8815-30.
231. Wong BK, Defeo-Jones D, Jones RE, et al. Psa-specific and non-psa-specific conversion of a psa-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos. 2001; 29: 313-8.
232. Kumar SK, Williams SA, Isaacs JT, et al. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem. 2007; 15: 4973-84.
233. Defeo-Jones D, Brady SF, Feng DM, et al. A prostate-specific antigen (psa)-activated vinblastine prodrug selectively kills psa-secreting cells in vivo. Mol Cancer Ther. 2002; 1: 451-9.
234. Brady SF, Pawluczyk JM, Lumma PK, et al. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. J Med Chem. 2002; 45: 4706-15.
235. Dubois V, Dasnois L, Lebtahi K, et al. Cpi-0004na, a new extracellularly tumor-activated prodrug of doxorubicin: In vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. Cancer Res. 2002; 62: 2327-31.
236. Fernandez AM, Van Derpoorten K, Dasnois L, et al. N-succinyl-(beta-alanyl-l-leucyl-l-alanyl-l-leucyl)doxorubicin: An extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J Med Chem. 2001; 44: 3750-3.
237. Pan C, Cardarelli PM, Nieder MH, et al. Cd10 is a key enzyme involved in the activation of tumor-activated peptide prodrug cpi-0004na and novel analogues: Implications for the design of novel peptide prodrugs for the therapy of cd10+ tumors. Cancer Res. 2003; 63: 5526-31.
238. Trouet A, Passioukov A, Van Derpoorten K, et al. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: Application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res. 2001; 61: 2843-6.
239. Dubois V, Nieder M, Collot F, et al. Thimet oligopeptidase (ec 3.4.24.15) activates cpi-0004na, an extracellularly tumour-activated prodrug of doxorubicin. Eur J Cancer. 2006; 42: 3049-56.
240. Choi Y, Weissleder R, and Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res. 2006; 66: 7225-9.
241. Choi Y, Weissleder R, and Tung CH. Protease-mediated phototoxicity of a polylysine-chlorin(e6) conjugate. Chem Med Chem. 2006; 1: 698-701.
242. Fiehn C, Kratz F, Sass G, et al. Targeted drug delivery by in vivo coupling to endogenous albumin: An albumin-binding prodrug of methotrexate (mtx) is better than mtx in the treatment of murine collagen-induced arthritis. Ann Rheum Dis. 2008; 67: 1188-91.
243. Pan H, Liu J, Dong Y, et al. Release of prostaglandin e(1) from n-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells. Macromol Biosci. 2008; 8: 599-605.
244. Pan H, Kopeckova P, Wang D, et al. Water-soluble hpma copolymer-prostaglandin e1 conjugates containing a cathepsin k sensitive spacer. J Drug Target. 2006; 14: 425-35.
245. Pan H, Sima M, Kopeckova P, et al. Biodistribution and pharmacokinetic studies of bone-targeting n-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm. 2008; 5: 548-58.
246. Kratz F, Drevs J, Bing G, et al. Development and in vitro efficacy of novel mmp2 and mmp9 specific doxorubicin albumin conjugates. Bioorg Med Chem Lett. 2001; 11: 2001-6.
247. Warnecke A, Fichtner I, Sass G, et al. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin b. Arch Pharm (Weinheim). 2007; 340: 389-95.
248. Gabriel D, Busso N, So A, et al. Thrombin-sensitive photodynamic agents: A novel strategy for selective synovectomy in rheumatoid arthritis. J Control Release. 2009; 138: 225-34.
249. Hamblin MR, Miller JL, Rizvi I, et al. Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res. 2001; 61: 7155-62.
250. Hamblin MR, Miller JL, Rizvi I, et al. Pegylation of charged polymer-photosensitiser conjugates: Effects on photodynamic efficacy. Br J Cancer. 2003; 89: 937-43.
251. Gabriel D, Campo MA, Gurny R, et al. Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes. Bioconjug Chem. 2007; 18: 1070-7.
252. Campo MA, Gabriel D, Kucera P, et al. Polymeric photosensitizer prodrugs for photodynamic therapy. Photochem Photobiol. 2007; 83: 958-65.
253. Chung DE and Kratz F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (upa). Bioorg Med Chem Lett. 2006; 16: 5157-63.
254. Jeffrey SC, Nguyen MT, Andreyka JB, et al. Dipeptide-based highly potent doxorubicin antibody conjugates. Bioorg Med Chem Lett. 2006; 16: 358-62.
255. Francisco JA, Cerveny CG, Meyer DL, et al. Cac10-vcmmae, an anti-cd30-monomethyl auristatin e conjugate with potent and selective antitumor activity. Blood. 2003; 102: 1458-65.
256. Hopewel JW, Duncan R, Wilding D, et al. Preclinical evaluation of the cardiotoxicity of pk2: A novel hpma copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol. 2001; 20: 461-70.
257. Galis ZS and Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis - the good, the bad, and the ugly. Circ Res. 2002; 90: 251-62.
258. Chipman SD, Oldham FB, Pezzoni G, et al. Biological and clinical characterization of paclitaxel poliglumex (ppx, ct-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine. 2006; 1: 375-83.
259. O'brien ME, Socinski MA, Popovich AY, et al. Randomized phase III trial comparing single-agent paclitaxel poliglumex (ct-2103, ppx) with single-agent gemcitabine or vinorelbine for the treatment of ps 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3: 728-34.
260. Paz-Ares L, Ross H, O'brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008; 98: 1608-13.
261. Dipaola RS, Rinehart J, Nemunaitis J, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol. 2002; 20: 1874-9.